What Caused Enveric Biosciences (ENVB) to Soar 74% in After-Hours Trading?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Source: Benzinga
Stock Performance: Enveric Biosciences Inc. (NASDAQ: ENVB) saw a significant after-hours stock increase of 73.82%, reaching $10.29, despite a 91.57% decline in value this year and a closing price of $5.92 on Tuesday.
Patent Allowance: The company received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent related to its EVM301 Series molecules, aimed at treating mental health disorders, which could enhance its product pipeline.
Company Statement: CEO Joseph Tucker emphasized the importance of reinforcing the patent estate around their lead asset, EB-003, and the EVM301 Series, viewing it as crucial for creating shareholder value.
Market Capitalization: Enveric has a market capitalization of $3.45 million, with its stock price fluctuating between $4.88 and $96.30 over the past year, and current trends indicate a negative price trajectory.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ENVB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ENVB
About ENVB
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The Company is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Enveric Biosciences Closes Direct Offering of Common Stock
- Funding Size: Enveric Biosciences successfully raised approximately $1.5 million by issuing 328,802 shares of common stock at $4.41 per share, with proceeds aimed at product development and working capital, enhancing the company's financial flexibility in the biotech sector.
- Warrant Issuance: The company concurrently issued series G and series H warrants, each allowing the purchase of 328,802 shares at an exercise price of $4.16 per share, with series G warrants expiring in five years and series H in eighteen months, thereby increasing investor engagement potential.
- Market Compliance: This offering was conducted under Nasdaq rules and an effective SEC registration statement, ensuring compliance and laying a foundation for future capital market activities, thus enhancing the company's credibility among investors.
- Strategic Development: With this financing, Enveric plans to accelerate the development of its neuroplastogenic small molecule therapies, particularly innovative drugs targeting psychiatric and neurological disorders, demonstrating the company's strategic commitment to addressing unmet medical needs.
Continue Reading
Enveric Biosciences Announces Direct Offering of Shares
- Offering Size: Enveric Biosciences is selling 328,802 shares at $4.41 each, expecting gross proceeds of approximately $1.5 million, which will be allocated for product development and working capital to enhance financial flexibility.
- Warrant Issuance: The company will issue Series G and Series H warrants, each exercisable for 328,802 shares at an exercise price of $4.16, with Series G warrants valid for five years and Series H for eighteen months, providing potential upside for investors.
- Market Reaction: Following the financing announcement, Enveric's shares fell over 12.5% in premarket trading, indicating market concerns regarding the offering and potentially impacting investor confidence.
- Transaction Timeline: The offering is expected to close on or about January 28, 2026, marking a further step in the company's capital market activities despite facing market volatility.
Continue Reading